Navigation Links
Aurora in Biological Technology

Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced today that the lead compounds of its Aurora kinase and VEGFR dual inhibitor program met a significant development milestone. Aurora kinase is a critical signaling enzyme whose function is required for c...

EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076

ROCKVILLE, Md., Jan. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigati...

CIO Leadership Series: Phil Loftus, Aurora Health Care

Milwaukee, Wis. - Phil Loftus has a huge task as chief information officer and vice president of information systems for Aurora Health Care . He's in charge of defining and implementing the information services component of Aurora's strategic goal - to provide an integrated approach to the d...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...out ENMD-2076 ENMD-2076 is an orally-active, aurora A/angiogenic kinase inhibitor with a unique kinase... angiogenic tyrosine kinase targets in addition to aurora A kinase and other oncogenic proteins. aurora kinases are key regulators of mitosis (cell divisi...

Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor

... targets with different mechanisms of action in clinical development which have been discovered and developed by NMS. These include inhibitors of CDK, aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the FDA in January this year and the first patients were treated with the compound in Apri...

Telik Reports Preclinical Results at AACR Annual Meeting

...erization and Mechanism of Action of Orally Active aurora Kinase/ VEGFR Inhibitors; Abstract # 1764 aurora kinases are Ser/Thr kinases that play an important...nd cytokinesis during mitosis. Over-expression of aurora kinases has been demonstrated in both solid tumors...

Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences

...Bi) Pharmaceutical and Biotechnology Growth Strategy Leadership Award ApaTech -- 2009 North American Device Biologics Company of the Year Award aurora Imaging Technology, Inc. -- 2009 North American Magnetic Resonance Imaging (MRI) Scanners Vertical Market Penetration Leadership Award Biotrove --...

MichBio Announces Annual Business Meeting Keynote and Pre-Meeting Workshop

...ylli was president and CEO of CovX Pharmaceuticals. Dr. Stylli co-founded aurora Biosciences in 1995, and in 2001 he was key to the success of Aurora's acqu...lowing the merger, Dr. Stylli continued on with the company as president of aurora Biosciences and Panvera. From 1987 to 1995, Dr. Stylli held various positi...

Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial

...n-G video is an animated tour-de-force of Science Communications. Winning both the Bronze Telly Award for film and video productions and the Platinum aurora Award (Best of Show) for excellence in independent film-making, the Rexin-G video is a triumph of Art in the service of Science, in the service of Med...

Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer

...s and a greater degree of therapeutic control. Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin. ...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

...une system. ENMD-2076 is an orally-active, aurora A/angiogenic kinase inhibitor with a unique kinase... angiogenic tyrosine kinase targets in addition to aurora A kinase and other oncogenic proteins. Aurora kina...ddition, ENMD-2076 is relatively selective for the aurora A isoform in comparison to...

Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer

...d a greater degree of therapeutic control. Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin. ...

Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008

...nd a greater degree of therapeutic control. Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin. ...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

...or regression, in multiple xenograft models (e.g. breast, colon, leukemia). aurora kinases are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. In addition to the aurora A isoform, ENMD-2076 has been shown to inhibit a distinct profile of angiog...

EntreMed Reports Second Quarter 2008 Financial Results

...resents a purchase price adjustment milestone triggered by the dosing of the first patient in a clinical trial for ENMD-2076, the lead molecule in our aurora kinase program acquired from Miikana Therapeutics in January 2006. The Company did not report any revenues for the first six months of 2008, althoug...

David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO

...ed of therapeutics with improved safety profiles. Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin. ...

Corgenix Expands Scientific Advisory Board

...guidance required for the successful development, manufacturing and marketing of our diagnostic testing products." Dr. Molk has been affiliated with aurora Denver Cardiology Associates since 1976 and has served as Chief of Cardiology at Sky Ridge Medical Center since 2003. He is board certified in interna...

Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team

... Coca Cola Company. Grayson was a founding member of the management team of aurora Biosciences and the founding chairman, CEO and president of Senomyx, Inc. H...es, including board member, general counsel and chief knowledge officer, at aurora Biosciences Corporation (now Vertex Pharmaceuticals, VRTX,) a publicly-trad...

Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor

...MD-2076 is a novel, selective kinase inhibitor with potent activity against aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory d...ved cancer drugs. ENMD-2076 is unique-in-class because it not only inhibits aurora A selectively, it also inhibits a cluster of kinases that are important for...

EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session

...ue combination of antiangiogenic, cell cycle, and antiproliferative activities. In preclinical studies, ENMD-2076 demonstrated potent activity against aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative a...

EntreMed Announces 2008 Corporate and Clinical Program Priorities

...or regression in breast, colon, and leukemia models without cardiovascular effects. ENMD-2076 is a unique-in-class compound that inhibits both aurora A and growth factor receptors critical to angiogenesis. -- EntreMed's IND has been accepted by the FDA and a Phase 1 study in solid tumors is...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results

... be completed this year. -- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial of SNS-314, a potent and selective inhibitor of aurora kinases A, B and C, in advanced solid tumors. To date, SNS-314 has been well tolerated and no dose-limiting toxicities have been observed. T...

Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report

...ti-microtubule, apoptosis, Bcl-2/Bcl-xL, TRAIL, vascular disrupting agents, Ras, Raf, MEK, mTOR, PI3, AKT, IGF-1, HSP90, HDAC, JAK/STAT, MAGE-A3, CDK, aurora Kinase, and anticoagulation. MedPredict conducted primary, qualitative interviews with renowned US-based Thought Leaders in the areas of non-small c...

Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting

... Congress Center, Atlanta, Georgia. AT9283 is an inhibitor of the kinases aurora A, aurora B, JAK2, BCR-Abl and Flt-3. There is strong evidence for an important role ...

Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

... least one new product into development every year." In addition to AT7519 and AT13148, Astex is developing: - AT9283, a multi-targeted inhibitor of aurora kinases, JAK2 and BCR-Abl, currently in multiple Phase 1 and Phase 1/2 multi-center clinical trials; - AT13387, a selective inhibitor of Hsp90, for w...

Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

...e 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an aurora kinase inhibitor, is currently being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis ...

Rigel to Present Research Programs at Scientific Conferences

...red a new class of small molecule PLK1 inhibitors using its image-based high content screening capabilities, which were previously used to discover an aurora Kinase inhibitor that is currently in clinical studies as a potential cancer therapeutic. Rigel's scientific team will also be presenting a poster at...

Wisconsins Real-Time" Economy

... markets. A real-time economy functions in real time on a global basis and without boundaries. In Wisconsin, GE Medical Systems, EPIC Systemsns and aurora Healthcare are revolutionizing the patient healthcare experience with web based patient record management solutions. Small entrepreneurial companies l...

Growth: the Good, the Bad, and the Ugly

...ssay kits. The company raised about $4M in angel funding, and was bought by aurora BioSciences in 2001. Since then, aurora was bought by Vertex , and PanVera was re-sold to Invitrogen . According ...

Aurora Selects New Imaging Technology

... MILWAUKEE,WI -- aurora Health Care is planning to open a new state-of-art...than 100 clinics and 135 community pharmacies. The aurora hospitals include: St. Lukes Medical Center, St. Lukes South Shore, aurora Sinai Medical Center, West Allis Memorial Hospital...

Aurora Health to provide eICU care

... MILWAUKEE - aurora Health Care , based in Milwaukee, will become the ...ed to 80 ICU beds at St. Luke's Medical Center and aurora Sinai Medical Center, both in Milwaukee, and aurora Medical Center in Kenosha. "This technology has ...

Milwaukee's PointOne appoints new president and CEO

...ill continue to build upon its collaboration with aurora Health Care to develop its next generation of mol...e personalized medical care model that two million aurora patients have utilized. aurora Health Care is a not-for-profit Wisconsin health c...

Ralph Kauten on how to raise angel financing

...mpany into an extremely successful operation. In March 2001, PanVeras investors received a healthy return on their investment when PanVera merged with aurora Biosciences. People have entrusted you with their money. Do something that makes sense. A few years after Kauten founded PanVera, some professors ...

An entrepreneurial success story Frank Langley champions biocapitalism

...rganizations provide treatment for these diseases at the earliest possible stages. To achieve this end, PointOne has already begun to collaborate with aurora Healthcare to identify patients at higher risk for developing breast cancer and congestive heart failure. Were not doing the physicians job, Langle...

Historic observatory becomes hot property on Lake Geneva

...offer. The residents are looking for partnerships or investors, such as aurora University, which owns a neighboring property, George Williams College. But aurora will only bite if it can at least avoid losing money running the observator...

New biomedical institute aims to unite business and academia in SE Wisconsin

...fied private donations have already been pledged by the Medical College , aurora Health Care , Cerner Corp . and GE Healthcare Technolgies . The hope is t...ecord to build on," Santiago said. "Then you have companies like Cerner and aurora participating in this because they see real value. If you can get that kind...

Having two biomedical tech centers in Wisconsin will help the state

...s northwest side, will be funded by both private and public dollars. Unspecified donations have already been made by the Medical College of Wisconsin, aurora Health Care, Cerner Corp. and GE Healthcare Technologies, one of the corporate powerhouses of Wisconsin. The institute will involve five UW-Milwau...

Digitizing hospitals with the right tools

...m rather than training our people to defeat them." Jack Steinman, CIO at aurora Healthcare, said he was very impressed with the comprehensive records that Marshfield had developed. He said aurora is trying to develop a similar method of working with electronic records, s...

Schrage: Don't think of distance learning as just automation

...municating with each other. Michael Maier, an instructional designer for aurora Healthcare Systems in Milwaukee who attended the Distance Teaching and Lear...es to communication and learning. Nevertheless, Maier pointed out, when aurora recently adopted instant messaging across the enterprise, people immediatel...

Katrina's destruction likely to speed up electronic healthcare records adoption

...el Gorczynski, director of medical informatics at aurora Healthcare in Milwaukee. "Paper is a very fragile...ready been made in Wisconsin by private companies. aurora alone currently has records for about 3.5 million ... one emergency room visit up through those who use aurora facilities and staff for their primary care. Wh...
Other Tags
(Date:7/23/2014)... around the world by 2050, according to one of ... Change (IPCC), may be advantageous to the physiology and ... of forage plants such as Stylosanthes capitata Vogel ... countries such as Brazil., The conclusion is from a ... Biology at the Ribeiro Preto Faculty of Philosophy, Sciences ...
(Date:7/23/2014)... MA -- What do mollusks, starfish, and corals ... habitat, they are all calcifiersorganisms that use calcium ... and shells for stability and protection. , The ... published by the Marine Biological Laboratory, addresses the ... changes worldwide. , As atmospheric carbon dioxide rises, ...
(Date:7/23/2014)... 23, 2014   MedNet Solutions , a ... study management systems, is pleased to announce that ... sciences industry executive with over 25 years of ... Clareece will be responsible for MedNet,s day-to-day operating ... and quality product/service delivery.  "We ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... the University of Exeter has developed a simple, ... frequently fatal lung disease which attacks immune deficient ... transplant recipients. , The lateral-flow device (LFD), created ... a notoriously difficult to diagnose disease caused by ... , Invasive aspergillosis is a leading cause of ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... in Shaanxi province, and the University of California, Davis, ... groundwork for establishing the Sino-U.S. Joint Research Center for ... held in the city of Yingchuan, China, during a ... Agriculture and China,s Ministry of Science and Technology. , ... and for our World Food Center and serves as ...
(Date:7/23/2014)... Thousands of DePuy Pinnacle hip lawsuits ... federal multidistrict litigation underway in U.S. District Court, Northern ... an Order dated July 18th, U.S. District Judge Ed ... a $1,000 fee for the preservation and return of ... things, the Order noted that there is no evidence ...
Breaking Medicine News(10 mins):Health News:New device detects deadly lung disease 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4
Other Contents